Treatment of recurrence of hepatitis B in transplant patients

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Berenguer, Marina ^a   Wright, Teresa L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE;

CONFERENCE PAPER; DNA HYBRIDIZATION; GRAFT REJECTION; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REINFECTION; SURVIVAL RATE; SURVIVAL TIME; VIRUS DETECTION;

EID: 0141637176     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00350-7     Document Type: Conference Paper

References (27)

1. United Network for Organ Sharing Web Site. Available at www.unet.org. Accessed January 31, 2000.
2. Todo S, Demetris A, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-626.
3. Berenguer M, Wright TL. Antiviral therapy pre- and post-transplantation. In: Maddrey W, Sorrell M, Schiff E, editors. Transplantation of the liver. Lippincott Williams and Wilkins; 2000. p. 343-360.
4. Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts J, et al. 'Occult' hepatitis B viral infection: An important source of transmission to the liver transplant recipient. Lancet 1994;343:142-146.
5. Steinmueller T, Seehofer D, Rayes N, Mueller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528-1535.
6. Terrault NA, Zhou S, McGory RW, Pruett TL, Lake JR, Roberts JP, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immune globulin. Hepatology 1998;28:555-561.
7. Prieto M, Gómez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001;7:51-58.
8. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-1674.
9. Crespo J, Fabrega E, Casafont F, Rivero M, de las Heras G, de la Peña J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999;5:175-183.
10. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for recurrent hepatitis B after liver transplantation. Hepatology 1999;29:1581-1586.
11. Fontana RJ, Harm HW, Wright T, Everson G, Baker A, Schiff ER, et al. multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001;7:504-510.
12. Rayes N, Seehofer D, Hopf U, Neuhaus R, Naumann U, Bechstein WO, et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001;71:96-101.
13. AI Faraidy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997;64:926-928.
14. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998;65:1615-1621.
15. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001;7:113-117.
16. Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998;29:985-989.
17. Malkan G, Cattral M, Humar A, Al Asghar H, Creig P, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000;69:1403-1407.
18. Locamini S, Hepatitis B, virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998;27:294-297.
19. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
20. Allen M, Deslauriers M, Andrews C, Tipples GA, Waiters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-1677.
21. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
22. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-1673.
23. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
24. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-273.
25. Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001;49:860-863.
26. Waist KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001;49:436-440.
27. Chalasani N, Smallwood G, Halcomb J, Fried MW, Boyer TD. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998;4:128-132.